logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Immunology and Allergy

Results

Drugs

October 2018

Apremilast for oral ulcers in active Behçet’s disease

Apremilast works by suppressing the activity of inflammatory pathway caused by molecules such as interleukins and tumour necrosis factors. In turn this reduces inflammation. Currently, specific curative treatment options for Behçet’s disease are very limited and treatment relies on controlling symptoms and relieving pain. Apremilast has shown promise in targeting oral ulcers in patients with Behçet’s disease, and if licensed it could be an effective treatment option for this patient group.

Drugs

March 2018

Lenabasum for Diffuse Cutaneous Systemic Sclerosis

Lenabasum is being developed for diffuse cutaneous SS as a tablet to be taken twice per day. It works by binding to immune cells and triggers a process which reduces inflammation and the scaring and thickening of tissues which usually happens in SS. If licensed, lenabasum has the potential to reduce the scaring which happens in diffuse cutaneous SS and improve symptoms.

Drugs

January 2018

Tocilizumab (RoActemra) for Adults with Giant Cell Arteritis – intravenous injection

Tocilizumab is a disease modifying drug that acts by blocking specific proteins that signal the inflammatory processes affecting blood vessels in GCA. It is currently licensed for the treatment of GCA in adults as a subcutaneous (under the skin) injection, but reactions at the place of injection include redness, itching and pain. It is anticipated that these reactions would be avoided if the drug was given as an intravenous infusion.

Drugs

May 2017

AR101 peanut allergy immunotherapy for adult and paediatric patients

AR101 is a form of treatment for peanut allergy. This treatment is administered orally with the aim of reeducatingthe body’s immune system, in order to increase the level at which the body reacts to peanuts, or toreduce the allergic response. The drug is targeted at adults and children with severe peanut allergy.Phase III clinical trials …

Drugs

April 2017

Lanadelumab for prevention of attacks in adults and adolescents with Type I and Type II hereditary angioedema

Angioedema is a rare blood disorder characterised by rapid swelling below the skin. Most often affect are hands, feet, eyes, lips or genitals. The swelling is caused by a collection of fluid in the deep layers of the skin. Hereditary Angioedema (HAE) is a rare condition caused by mutations that reduce the production or expression …

Drugs

April 2017

ECCS-50 (Cytori stem cell therapy) for moderate to severe hand dysfunction due to Scleroderma

ECCS-50 (Cytori stem cell therapy) is a new treatment intended for the treatment of moderate to severe hand problems in people with scleroderma. It involves taking stem cells (a cell with the potential to become any cell type) from patient’s fat tissue and reinjecting these cells into the hands. Clinical trials on ECCS-50 are currently …

Drugs

April 2017

Viaskin Peanut – peanut allergy immunotherapy (DBV 712; EPIT Peanut) for paediatric patients aged 4-11

Viaskin Peanut is a novel form of allergy immunotherapy in development. A patch worn on intact skin is used to deliver peanut allergens. The allergens are given to trigger an effect in the immune system with the aim of desensitising an allergy sufferer to peanuts and reducing future reactions to the allergen. The patch is …

Drugs

Drugs

Drugs

January 2017

Dupilumab for bilateral nasal polyposis and chronic sinusitis – second line

Dupilumab is a new drug to treat nasal polyps, which are swellings in the lining of the nose and sinuses (air-filled spaces behind the nose, eyes and cheeks). They can cause a blocked or runny nose, and may reduce the sense of smell. Dupilumab is injected under the skin and may help reduce nasal symptoms. …

Get Alerts